{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:35:22Z","timestamp":1781231722438,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012399","name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["contract HHSO100201400004I, order HHSO10033001T"],"award-info":[{"award-number":["contract HHSO100201400004I, order HHSO10033001T"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An unprecedented number of human infections with avian influenza A(H7N9) in the fifth epidemic wave during the winter of 2016\u20132017 in China and their antigenic divergence from the viruses that emerged in 2013 prompted development of updated vaccines for pandemic preparedness. We report on the findings of a clinical study in healthy adults designed to evaluate the safety and immunogenicity of three dose levels of recombinant influenza vaccine derived from highly pathogenic A\/Guangdong\/17SF003\/2016 (H7N9) virus adjuvanted with AS03 or MF59 oil-in water emulsions. Most of the six study groups meet the FDA CBER-specified vaccine licensure criterion of 70% seroprotection rate (SPR) for hemagglutination inhibition antibodies to the homologous virus. A substantial proportion of subjects show high cross-reactivity to antigenically distinct heterologous A(H7N9) viruses from the first epidemic wave of 2013. These results provide critical information to develop a pandemic response strategy and support regulatory requirements for vaccination under Emergency Use Authorization.<\/jats:p>","DOI":"10.1038\/s41541-021-00287-7","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T13:05:27Z","timestamp":1616159127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults"],"prefix":"10.1038","volume":"6","author":[{"given":"Christine M.","family":"Oshansky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrina","family":"Pavetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Horwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Biscardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Treanor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Jepson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BPI17002 Study Coordination Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Colfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Hylton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvija","family":"Tresnjak-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2879-2612","authenticated-orcid":false,"given":"Rick A.","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cioce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-8312","authenticated-orcid":false,"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"287_CR1","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao, R. et al. Human infection with a novel avian-origin influenza A(H7N9) virus. N. Engl. J. Med. 368, 1888\u20131897 (2013).","journal-title":"N. Engl. J. Med."},{"key":"287_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/S0140-6736(13)60938-1","volume":"381","author":"D Liu","year":"2013","unstructured":"Liu, D. et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 381, 1926\u20131932 (2013).","journal-title":"Lancet"},{"key":"287_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jfma.2017.02.011","volume":"116","author":"JR Yang","year":"2017","unstructured":"Yang, J. R. & Liu, M. T. Human infection caused by an avian influenza A(H7N9) virus with a polybasic cleavage site in Taiwan, 2017. J. Formos. Med. Assoc. 116, 210\u2013212 (2017).","journal-title":"J. Formos. Med. Assoc."},{"key":"287_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01277-17","volume":"91","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in Mainland China.J. Virol. 91, e01277-17 (2017).","journal-title":"J. Virol."},{"key":"287_CR5","unstructured":"WHO. Antigenic and Genetic Characteristics of Zoonotic Influenza Viruses and Development of Candidate Vaccine Viruses for Pandemic Preparedness, http:\/\/www.who.int\/influenza\/vaccines\/virus\/201703_zoonotic_vaccinevirusupdate.pdf?ua=1 (2017)."},{"key":"287_CR6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3201\/eid2410.171063","volume":"24","author":"J Lu","year":"2018","unstructured":"Lu, J. et al. Molecular evolution, diversity, and adaptation of influenza A(H7N9) viruses in China. Emerg. Infect. Dis. 24, 1795\u20131805 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"287_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.15585\/mmwr.mm6635a2","volume":"66","author":"JC Kile","year":"2017","unstructured":"Kile, J. C. et al. Update: increase in human infections with novel Asian lineage avian influenza A(H7N9) viruses during the fifth epidemic\u2014China, October 1, 2016\u2013August 7, 2017. MMWR Morb. Mortal. Wkly. Rep. 66, 928\u2013932 (2017); erratum 66, 1084 (2017).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"287_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004384","volume":"4","author":"A Banzhoff","year":"2009","unstructured":"Banzhoff, A. et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4, e4384 (2009).","journal-title":"PLoS ONE"},{"key":"287_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jama.2014.12609","volume":"312","author":"RB Belshe","year":"2014","unstructured":"Belshe, R. B. et al. Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 312, 1420\u20131428 (2014).","journal-title":"JAMA"},{"key":"287_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1086\/527489","volume":"197","author":"DI Bernstein","year":"2008","unstructured":"Bernstein, D. I. et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197, 667\u2013675 (2008).","journal-title":"J. Infect. Dis."},{"key":"287_CR11","doi-asserted-by":"publisher","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","volume":"1","author":"WH Chen","year":"2014","unstructured":"Chen, W. H. et al. Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant. Open Forum Infect. Dis. 1, ofu091 (2014).","journal-title":"Open Forum Infect. Dis."},{"key":"287_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jama.2015.7916","volume":"314","author":"LA Jackson","year":"2015","unstructured":"Jackson, L. A. et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA 314, 237\u2013246 (2015).","journal-title":"JAMA"},{"key":"287_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/infdis\/jis427","volume":"206","author":"LA Jackson","year":"2012","unstructured":"Jackson, L. A. et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J. Infect. Dis. 206, 811\u2013820 (2012).","journal-title":"J. Infect. Dis."},{"key":"287_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jama.2014.12854","volume":"312","author":"MJ Mulligan","year":"2014","unstructured":"Mulligan, M. J. et al. Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 312, 1409\u20131419 (2014).","journal-title":"JAMA"},{"key":"287_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa055778","volume":"354","author":"JJ Treanor","year":"2006","unstructured":"Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T. & Wolff, M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354, 1343\u20131351 (2006).","journal-title":"N. Engl. J. Med."},{"key":"287_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.vaccine.2018.11.069","volume":"37","author":"CM Oshansky","year":"2019","unstructured":"Oshansky, C. M. et al. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). Vaccine 37, 435\u2013443 (2019).","journal-title":"Vaccine"},{"key":"287_CR17","doi-asserted-by":"publisher","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","volume":"6","author":"SA Bart","year":"2014","unstructured":"Bart, S. A. et al. A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults. Sci. Transl. Med 6, 234ra55 (2014).","journal-title":"Sci. Transl. Med"},{"key":"287_CR18","unstructured":"FDA. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines (US FDA, 2007)."},{"key":"287_CR19","unstructured":"U.S. Homeland Security Council. National Strategy for Pandemic Influenza. https:\/\/www.cdc.gov\/flu\/pandemic-resources\/pdf\/pandemic-influenza-strategy-2005.pdf (2005)."},{"key":"287_CR20","unstructured":"U.S. Homeland Security Council. National Strategy for Pandemic Influenza Implementation Plan. https:\/\/www.cdc.gov\/flu\/pandemic-resources\/pdf\/pandemic-influenza-implementation.pdf (2006)."},{"key":"287_CR21","unstructured":"Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Interim Updated Planning Guidance on Allocating and Targeting Pandemic Influenza Vaccine During an Influenza Pandemic. https:\/\/www.cdc.gov\/flu\/pandemic-resources\/pdf\/2018-Influenza-Guidance.pdf (2018)."},{"key":"287_CR22","unstructured":"U.S. Department of Health and Human Services. Pandemic Influenza Plan 2017 Update. https:\/\/www.cdc.gov\/flu\/pandemic-resources\/pdf\/pan-flu-report-2017v2.pdf (2017)."},{"key":"287_CR23","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1016\/j.vaccine.2017.03.048","volume":"35","author":"M Cox","year":"2017","unstructured":"Cox, M. Modern technology: the preferred biosecurity strategy? Vaccine 35, 5949\u20135950 (2017).","journal-title":"Vaccine"},{"key":"287_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2051013615595595","volume":"3","author":"MM Cox","year":"2015","unstructured":"Cox, M. M., Izikson, R., Post, P. & Dunkle, L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther. Adv. Vaccines 3, 97\u2013108 (2015).","journal-title":"Ther. Adv. Vaccines"},{"key":"287_CR25","unstructured":"WHO. Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness. https:\/\/www.who.int\/influenza\/vaccines\/virus\/201909_zoonotic_vaccinevirusupdate.pdf?ua=1 (2019)."},{"key":"287_CR26","unstructured":"WHO. Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness https:\/\/www.who.int\/influenza\/vaccines\/virus\/201709_zoonotic_vaccinevirusupdate.pdf?ua=1 (2017)."},{"key":"287_CR27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/infdis\/jiz295","volume":"220","author":"W Zhong","year":"2019","unstructured":"Zhong, W. & Levine, M. Z. Stockpiled avian influenza A(H7N9) vaccines induce robust, nonneutralizing functional antibodies against antigenically drifted fifth-wave A(H7N9) viruses. J. Infect. Dis. 220, 1276\u20131280 (2019).","journal-title":"J. Infect. Dis."},{"key":"287_CR28","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.vaccine.2019.03.071","volume":"37","author":"HM El Sahly","year":"2019","unstructured":"El Sahly, H. M. et al. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A\/H7N7-H7N9 vaccination. Vaccine 37, 2561\u20132568 (2019).","journal-title":"Vaccine"},{"key":"287_CR29","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.vaccine.2017.02.057","volume":"35","author":"A Madan","year":"2017","unstructured":"Madan, A. et al. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: a phase II, observer-blind, randomized, controlled trial. Vaccine 35, 1865\u20131872 (2017).","journal-title":"Vaccine"},{"key":"287_CR30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.vaccine.2017.01.054","volume":"35","author":"A Madan","year":"2017","unstructured":"Madan, A. et al. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: a phase I\/II, observer-blind, randomized, controlled trial. Vaccine 35, 1431\u20131439 (2017).","journal-title":"Vaccine"},{"key":"287_CR31","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jip.2011.05.003","volume":"107","author":"MM Cox","year":"2011","unstructured":"Cox, M. M. & Hashimoto, Y. A fast track influenza virus vaccine produced in insect cells. J. Invertebr. Pathol. 107, S31\u2013S41 (2011).","journal-title":"J. Invertebr. Pathol."},{"key":"287_CR32","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf (2017)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00287-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:30:28Z","timestamp":1670023828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00287-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00287-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}